Fennec Pharmaceuticals Inc(NASDAQ:FENC) 
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced heari...
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 5.42
H 5.61
L 5.10
C 5.25
V 172,837
10EMA 5.25
20EMA 5.25
60EMA 5.25
120EMA 5.25
250EMA 5.25